- Home
- RIGL vs NBH Comparison
RIGL vs NBH Comparison
Compare RIGL & NBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- NBH
- Stock Information
- Founded
- RIGL 1996
- NBH 2002
- Country
- RIGL United States
- NBH United States
- Employees
- RIGL N/A
- NBH N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- NBH Finance/Investors Services
- Sector
- RIGL Health Care
- NBH Finance
- Exchange
- RIGL Nasdaq
- NBH Nasdaq
- Market Cap
- RIGL 298.0M
- NBH 291.1M
- IPO Year
- RIGL 2000
- NBH N/A
- Fundamental
- Price
- RIGL $17.28
- NBH $9.74
- Analyst Decision
- RIGL Buy
- NBH
- Analyst Count
- RIGL 5
- NBH 0
- Target Price
- RIGL $36.80
- NBH N/A
- AVG Volume (30 Days)
- RIGL 222.1K
- NBH 85.9K
- Earning Date
- RIGL 05-06-2025
- NBH 01-01-0001
- Dividend Yield
- RIGL N/A
- NBH 4.34%
- EPS Growth
- RIGL N/A
- NBH N/A
- EPS
- RIGL 0.99
- NBH 0.12
- Revenue
- RIGL $179,278,000.00
- NBH N/A
- Revenue This Year
- RIGL $12.53
- NBH N/A
- Revenue Next Year
- RIGL $15.68
- NBH N/A
- P/E Ratio
- RIGL $17.36
- NBH $87.04
- Revenue Growth
- RIGL 54.71
- NBH N/A
- 52 Week Low
- RIGL $7.48
- NBH $8.75
- 52 Week High
- RIGL $29.82
- NBH $11.01
- Technical
- Relative Strength Index (RSI)
- RIGL 44.84
- NBH 31.56
- Support Level
- RIGL $16.05
- NBH $9.80
- Resistance Level
- RIGL $17.52
- NBH $9.98
- Average True Range (ATR)
- RIGL 1.26
- NBH 0.20
- MACD
- RIGL 0.10
- NBH -0.04
- Stochastic Oscillator
- RIGL 63.57
- NBH 20.95
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About NBH Neuberger Berman Municipal Fund Inc.
Neuberger Berman Municipal Fund Inc is a closed-end management investment company that invests mainly in municipal securities. The company aims to provide common stockholders a high level of current income exempt from Federal income tax.